Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319755 | 0.89 | GBA1 (0.46) | GBA1SIGMAR1SLC18A3HRH1SLC6A2 | |
| SCHEMBL2242592 | 0.86 | ALDH1A1 (0.41) | GBA1 | |
| SCHEMBL2241838 | 0.82 | GRIN1 (0.42) | — | |
| SCHEMBL1796446 | 0.80 | GRIN1 (0.45) | SIGMAR1MEN1KMT2A | |
| SCHEMBL5387078 | 0.74 | ALDH1A1 (0.39) | SIGMAR1 | |
| SCHEMBL4695264 | 0.70 | GRIN2B (0.46) | GBA1SIGMAR1 | |
| SCHEMBL12539609 | 0.69 | GBA1 (0.70) | GBA1SIGMAR1SLC18A3HRH1SLC6A2 | |
| SCHEMBL87612 | 0.69 | GBA1 (1.00) | GBA1SIGMAR1SLC18A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3629625 | 0.69 | GRIN2B (0.45) | GBA1SIGMAR1 | |
| SCHEMBL3598195 | 0.69 | BACE1 (0.53) | GBA1SIGMAR1SLC18A3HRH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | claimed |
| WO-2009076212-A1 | CATALYTIC TOPOISOMERASE II INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-06-18 | — | — | WO | claimed |
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | AMGEN INC. | 2006-03-02 | — | — | US | claimed |
| EP-1218384-A4 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-11-20 | — | — | EP | claimed |
| EP-1218384-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001023392-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| US-4746649-A | Diamino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1988-05-24 | — | — | US | claimed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055913-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-7674907-B2 | Furanopyridine derivatives and methods of use | AMGEN INC. (US) | 2010-03-09 | — | — | US | disclosed |
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2009076212-A1 | CATALYTIC TOPOISOMERASE II INHIBITORS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2007109098-A2 | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| EP-0486478-A2 | Renin-inhibiting peptides | THE UPJOHN COMPANY (US) | 1992-05-20 | — | — | EP | disclosed |
| US-4880781-A | HYPOTENSIVE AGENTS | THE UPJOHN COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4746649-A | Diamino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1988-05-24 | — | — | US | disclosed |
| EP-0173481-A2 | Peptides | THE UPJOHN COMPANY (US) | 1986-03-05 | — | — | EP | disclosed |
| EP-0161588-A2 | Diamino acid derivatives | MERCK PATENT GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060046977-A1 | Furanopyridine derivatives and methods of use | LCK, NFATC1, MINK1 | GBA1 2678/4885SIGMAR1 4617/4885SLC18A3 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.